VistaGen Therapeutics, Inc. Receivables

Receivables of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Receivables growth rates and interactive chart. Accounts receivable (AR) is the balance of money due to a firm for goods or services delivered or used but not yet paid for by customers. Accounts receivables are listed on the balance sheet as a current asset. AR is any amount of money owed by customers for purchases made on credit. When a company makes a sale, it records revenues and a corresponding balance in accounts receivable. When an invoice is paid, the accounts payable account is reduced and cash is received. Receivables should grow in-line with revenue over time, if they are growing much faster, a company might be booking revenue too aggressively.


Highlights and Quick Summary

  • Receivables for the quarter ending March 30, 2019 was $300 Thousand (a 0.0% decrease compared to previous quarter)
  • Year-over-year quarterly Receivables increased by 182.49%
  • Annual Receivables for 2019 was $300 Thousand (a 182.49% increase from previous year)
  • Annual Receivables for 2012 was $106 Thousand (a 151.66% increase from previous year)
Visit stockrow.com/VTGN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Receivables of VistaGen Therapeutics, Inc.

Most recent Receivablesof VTGN including historical data for past 10 years.

Interactive Chart of Receivables of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. Receivables for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $0.3 $0.3
2018 $0.3
2016 $1.25
2012 $0.11 $0.11
2011 $0.01 $0.13 $0.15 $0.04 $0.04

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.